Amyloidosis & Heart Devices: Longevity Study Results

Recent research has investigated the effectiveness of implantable cardioverter-defibrillators (ICDs) in individuals diagnosed with light-chain amyloidosis, a rare disease where abnormal proteins build up in organs, including the heart. The study, involving 233 participants, sought to determine if these devices could extend the lives of patients with the condition.

The Study and Its Findings

Researchers enrolled participants between January 2016 and December 2022. All participants had a diagnosis of light-chain amyloidosis and had received a cardiac implantable electronic device – specifically, an ICD. The primary goal was to assess the impact of these devices on overall survival.

What is Light-Chain Amyloidosis?

Light-chain amyloidosis occurs when abnormal proteins, known as light chains, accumulate in various organs. This buildup can disrupt normal organ function, and the heart is frequently affected, leading to arrhythmias and heart failure.

Did You Know? The study included participants from 46 centers across the United States and Europe.

Why This Research Matters

ICDs are commonly used in patients at risk of sudden cardiac arrest. However, the effectiveness of these devices in the context of amyloidosis – a disease with a complex and often unpredictable course – was previously unclear. The findings suggest that, in this specific patient population, ICDs did not demonstrate a statistically significant improvement in longevity.

The study’s results indicate that the median overall survival was similar in patients who received an ICD compared to those who did not. This challenges previous assumptions about the benefits of ICDs in amyloidosis and raises questions about current treatment strategies.

Expert Insight: The lack of a survival benefit with ICDs in this study highlights the challenges of applying standard cardiac treatments to patients with systemic diseases like amyloidosis, where the underlying pathology extends beyond the heart itself.

Potential Next Steps

Further research could focus on identifying specific subgroups of amyloidosis patients who might benefit from ICDs. The effectiveness of these devices varies depending on the stage of the disease, the extent of organ involvement, or other individual patient characteristics.

Researchers may also explore alternative or adjunctive therapies to improve outcomes in amyloidosis patients. A possible next step could involve investigating the role of newer treatment modalities targeting the underlying amyloid protein buildup. Analyses expect that continued monitoring of patients enrolled in the study could provide additional insights into the long-term effects of ICDs.

Frequently Asked Questions

What is an implantable cardioverter-defibrillator (ICD)?

An ICD is a small device implanted in the chest that can detect and correct life-threatening irregular heartbeats.

How many people participated in the study?

A total of 233 participants with light-chain amyloidosis were enrolled in the study.

Did the study show any benefit from using an ICD?

The study did not demonstrate a statistically significant improvement in overall survival for patients with light-chain amyloidosis who received an ICD.

How might these findings influence the way doctors treat amyloidosis in the future?